158 related articles for article (PubMed ID: 15235029)
21. Familial melanoma and p16--a hung jury.
Wainwright B
Nat Genet; 1994 Sep; 8(1):3-5. PubMed ID: 7987389
[No Abstract] [Full Text] [Related]
22. Alterations of the tumor suppressor genes CDKN2A (p16(INK4a)), p14(ARF), CDKN2B (p15(INK4b)), and CDKN2C (p18(INK4c)) in atypical and anaplastic meningiomas.
Boström J; Meyer-Puttlitz B; Wolter M; Blaschke B; Weber RG; Lichter P; Ichimura K; Collins VP; Reifenberger G
Am J Pathol; 2001 Aug; 159(2):661-9. PubMed ID: 11485924
[TBL] [Abstract][Full Text] [Related]
23. Lack of germ-line mutations of CDK4, p16(INK4A), and p15(INK4B) in families with glioma.
Gao L; Liu L; van Meyel D; Cairncross G; Forsyth P; Kimmel D; Jenkins RB; Lassam NJ; Hogg D
Clin Cancer Res; 1997 Jun; 3(6):977-81. PubMed ID: 9815774
[TBL] [Abstract][Full Text] [Related]
24. CDKN2A/CDK4 molecular study on 155 Italian subjects with familial and/or primary multiple melanoma.
Majore S; De Simone P; Crisi A; Eibenschutz L; Binni F; Antigoni I; De Bernardo C; Catricalà C; Grammatico P
Pigment Cell Melanoma Res; 2008 Apr; 21(2):209-11. PubMed ID: 18363633
[No Abstract] [Full Text] [Related]
25. Human melanoma genetics.
Kamb A
J Investig Dermatol Symp Proc; 1996 Apr; 1(2):177-82. PubMed ID: 9627713
[TBL] [Abstract][Full Text] [Related]
26. Evidence of a role for the INK4 family of cyclin-dependent kinase inhibitors in ovarian granulosa cell tumors.
Arcellana-Panlilio MY; Egeler RM; Ujack E; Magliocco A; Stuart GC; Robbins SM; Coppes MJ
Genes Chromosomes Cancer; 2002 Oct; 35(2):176-81. PubMed ID: 12203782
[TBL] [Abstract][Full Text] [Related]
27. Rarity of somatic and germline mutations of the cyclin-dependent kinase 4 inhibitor gene, CDK4I, in melanoma.
Ohta M; Nagai H; Shimizu M; Rasio D; Berd D; Mastrangelo M; Singh AD; Shields JA; Shields CL; Croce CM
Cancer Res; 1994 Oct; 54(20):5269-72. PubMed ID: 7923152
[TBL] [Abstract][Full Text] [Related]
28. Germline mutations of the INK4a-ARF gene in patients with suspected genetic predisposition to melanoma.
Soufir N; Lacapere JJ; Bertrand G; Matichard E; Meziani R; Mirebeau D; Descamps V; Gérard B; Archimbaud A; Ollivaud L; Bouscarat F; Baccard M; Lanternier G; Saïag P; Lebbé C; Basset-Seguin N; Crickx B; Cave H; Grandchamp B
Br J Cancer; 2004 Jan; 90(2):503-9. PubMed ID: 14735200
[TBL] [Abstract][Full Text] [Related]
29. CDKN2A and MC1R analysis in amelanotic and pigmented melanoma.
Ghiorzo P; Pastorino L; Pizzichetta MA; Bono R; Queirolo P; Talamini R; Annessi G; Bruno W; Nasti S; Gargiulo S; Battistuzzi L; Sini MC; Palmieri G; Scarrà GB;
Melanoma Res; 2009 Jun; 19(3):142-5. PubMed ID: 19339902
[TBL] [Abstract][Full Text] [Related]
30. Tumor suppression for ARFicionados: the relative contributions of p16INK4a and p14ARF in melanoma.
Peters G
J Natl Cancer Inst; 2008 Jun; 100(11):757-9. PubMed ID: 18505965
[No Abstract] [Full Text] [Related]
31. [The INK4a-ARF locus: role in the genetic predisposition to familial melanoma and in skin carcinogenesis].
Soufir N; Basset-Seguin N
Bull Cancer; 2001 Nov; 88(11):1061-7. PubMed ID: 11741799
[TBL] [Abstract][Full Text] [Related]
32. Genetic study of familial uveal melanoma: association of uveal and cutaneous melanoma with cutaneous and ocular nevi.
Smith JH; Padnick-Silver L; Newlin A; Rhodes K; Rubinstein WS
Ophthalmology; 2007 Apr; 114(4):774-9. PubMed ID: 17207529
[TBL] [Abstract][Full Text] [Related]
33. Genetic testing in hereditary melanoma.
Tsao H; Niendorf K
J Am Acad Dermatol; 2004 Nov; 51(5):803-8. PubMed ID: 15523363
[TBL] [Abstract][Full Text] [Related]
34. Abnormalities of p16, p15 and CDK4 genes in recurrent malignant astrocytomas.
Saxena A; Robertson JT; Ali IU
Oncogene; 1996 Aug; 13(3):661-4. PubMed ID: 8760309
[TBL] [Abstract][Full Text] [Related]
35. Deregulation of the TP53/p14ARF tumor suppressor pathway in low-grade diffuse astrocytomas and its influence on clinical course.
Watanabe T; Katayama Y; Yoshino A; Komine C; Yokoyama T
Clin Cancer Res; 2003 Oct; 9(13):4884-90. PubMed ID: 14581362
[TBL] [Abstract][Full Text] [Related]
36. Genetic testing for melanoma.
Kefford R; Bishop JN; Tucker M; Bressac-de Paillerets B; Bianchi-Scarrá G; Bergman W; Goldstein A; Puig S; Mackie R; Elder D; Hansson J; Hayward N; Hogg D; Olsson H;
Lancet Oncol; 2002 Nov; 3(11):653-4. PubMed ID: 12424065
[No Abstract] [Full Text] [Related]
37. Divergent expression of cyclin-dependent kinase inhibitors (CKI) and p14ARF/p16 beta in non-Hodgkin's lymphomas and chronic lymphocytic leukemia.
Pabst T; Peters UR; Tinguely M; Schwaller J; Tschan M; Aebi S; Vonlanthen S; Borisch B; Betticher DC; Zimmermann A; Tobler A; Fey MF
Leuk Lymphoma; 2000 May; 37(5-6):639-48. PubMed ID: 11042528
[TBL] [Abstract][Full Text] [Related]
38. Risk factors for the development of primary cutaneous malignant melanoma.
MacKie RM
Dermatol Clin; 2002 Oct; 20(4):597-600. PubMed ID: 12380046
[TBL] [Abstract][Full Text] [Related]
39. Screening for CDKN2A mutations in hereditary melanoma.
Goldstein AM; Tucker MA
J Natl Cancer Inst; 1997 May; 89(10):676-8. PubMed ID: 9168176
[No Abstract] [Full Text] [Related]
40. Adenovirus-mediated overexpression of p15INK4B inhibits human glioma cell growth, induces replicative senescence, and inhibits telomerase activity similarly to p16INK4A.
Fuxe J; Akusjärvi G; Goike HM; Roos G; Collins VP; Pettersson RF
Cell Growth Differ; 2000 Jul; 11(7):373-84. PubMed ID: 10939591
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
